Endologix Inc (ELGXQ1)

Sector:
HEALTH CARE
Industry:
HEALTH CARE SUPPLIES
SIC:
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
CEO:
John D. McDermott
Employees:
528
2 MUSICK, IRVINE, CA 92618
9495957200

*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Endologix, Inc. engages in the research, development, manufacture, and trade of medical devices for the treatment of aortic disorders such as abdominal aortic aneurysms (AAA). Its products include AFX Endovascular AAA System, VELA Proximal Endograft, Intuitrak Endovascular AAA System, and Nellix Endovascular Aneury® Sealing System. The company was founded in March 1992 and is headquartered in Irvine, CA.

Data derived from most recent annual or quarterly report
Market Cap 4.545 Million Shares Outstanding20.657 Million Avg 30-day Volume 6.198 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-2.14
Price to Revenue0.133 Debt to Equity6.7807 EBITDA-21.501 Million
Price to Book Value0.5845 Operating Margin-43.4195 Enterprise Value189.599 Million
Current Ratio0.268 EPS Growth0.383 Quick Ratio0.13
1 Yr BETA 0.7818 52-week High/Low 0.0 / Profit Margin-47.8903
Operating Cash Flow Growth-10.8547 Altman Z-Score-4.1594 Free Cash Flow to Firm -42.568 Million
View SEC Filings from ELGXQ1 instead.

View recent insider trading info

Funds Holding ELGXQ1 (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ELGXQ1

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Events (8k)

  • 8-K: filed on 2020-10-01:
    Item 8.01: Other Events
  • 8-K: filed on 2020-09-22:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-07-09:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 1.03: Bankruptcy or Receivership
    Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
    Item 2.04: Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-07-06:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-07-01:
    Item 1.01: Entry into a Material Definitive Agreement
  • 8-K: filed on 2020-06-24:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2020-06-19:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2020-06-15:
    Item 1.01: Entry into a Material Definitive Agreement
  • 8-K: filed on 2020-06-11:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2020-05-11:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 2.02: Results of Operations and Financial Condition
    Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
    Item 9.01: Financial Statements and Exhibits
    Item 8.01: Other Events
  • Proxy

    Prospectus

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    LEMAITRE DAN

    • Director
    0 2020-09-04 0

    WALLER GREGORY D

    • Director
    710 2020-08-12 0

    ONOPCHENKO JOHN CEO AND DIRECTOR

    • Officer
    • Director
    165,698 2020-08-12 0

    WILDER THOMAS

    • Director
    0 2020-08-12 0

    THOMPSON MATTHEW CHIEF MEDICAL OFFICER

    • Officer
    52,878 2020-08-12 0

    BRADY TIMOTHY NICHOLAS CONTROLLER AND CORP SECRETARY

    • Officer
    891 2020-08-12 0

    PINTO CYNTHIA BUCH INTERIM CFO

    • Officer
    6,304 2020-08-12 0

    FECHO JEFF CHIEF QUALITY OFFICER

    • Officer
    23,732 2020-08-05 0

    MOTT RICHARD W

    • Director
    0 2020-06-19 0

    MAHBOOB VASEEM CHIEF FINANCIAL OFFICER

    • Officer
    111,716 2020-03-24 0

    KIERNAN JANE E

    • Director
    103,847 2020-03-18 0

    ZEHREN JOHN CHIEF COMMERCIAL OFFICER

    • Officer
    40,138 2020-01-07 0

    HAYDEN JEREMY B. GENERAL COUNSEL

    • Officer
    32,040 2019-10-03 0

    ZENTY III THOMAS F

    • Director
    35,547 2019-08-05 0

    NORWALK LESLIE V

    • Director
    29,932 2019-08-05 0

    NEELS GUIDO J

    • Director
    43,200 2019-04-03 0

    CAMBER CAPITAL MANAGEMENT LP

    9,300,000 2018-10-29 0

    CHAVEZ CHRISTOPHER G.

    • Director
    378,346 2018-05-29 0

    MCDERMOTT JOHN D

    • Director
    879,423 2018-05-28 0

    NAGEL LAURA VP, QUALITY

    • Officer
    48,860 2018-03-13 0

    MITCHELL ROBERT D PRESIDENT

    • Officer
    316,886 2017-06-19 0

    O'QUINN SHARI L VP, CLINICAL & REGULATORY

    • Officer
    94,356 2017-05-31 0

    LIMA JOSE A. VP-QUALITY

    • Officer
    37,884 2016-08-19 0

    CHOBOTOV MICHAEL V. CHIEF TECHNOLOGY OFFICER

    • Officer
    189,269 2016-08-05 0

    DEJOHN JOSEPH A. GENERAL MANAGER, ASIA & PAC

    • Officer
    No longer subject to file 2016-07-08 0

    JENNINGS DAVID M. VP-HUMAN RESOURCES

    • Officer
    50,281 2016-06-01 0

    MACHEK JAMES EDWARD VP-RESEARCH & DEVELOPMENT

    • Officer
    38,286 2016-06-01 0

    DEPALMA AMANDA L. VP, GLOBAL MARKETING

    • Officer
    43,772 2016-06-01 0

    FERRACCI CECILE GENERAL MANAGER, EUROPE

    • Officer
    40,706 2016-02-04 0

    LOVE CHARLES STEELE VP-CLINICAL AFFAIRS

    • Officer
    45,037 2016-01-26 0

    ABRAHAM TODD VP OF OPERATIONS

    • Officer
    86,821 2015-11-13 0

    THUNEN SHELLEY B

    • NAMED EXECUTIVE OFFICER
    No longer subject to file 2015-10-19 0

    FAULS JANET MARY VP REGULATORY AFFAIRS

    • Officer
    82,492 2015-05-28 0

    LYONS RUTH ANNE VP GLOBAL MARKETING

    • Officer
    27,168 2014-03-14 0

    SCHRECK STEFAN VICE PRESIDENT

    • Officer
    No longer subject to file 2013-10-11 0

    GREENSTEIN LEONARD M. VP FINANCE & CORP CONTROLLER

    • Officer
    No longer subject to file 2013-10-03 0

    SORSHER GARY I. VICE PRESIDENT - QUALITY

    • Officer
    No longer subject to file 2013-09-27 0

    TYLER MARTIN VP, INTERNATIONAL

    • Officer
    14,472 2013-03-15 0

    DE GREEF RODERICK

    • Director
    7,102 2013-03-08 0

    KRIST ROBERT JOHN CHIEF FINANCIAL OFFICER

    • Officer
    142,236 2012-12-28 0

    ESSEX WOODLANDS HEALTH VENTURES FUND VII LP

    • 10% Owner
    1,165,428 2012-11-01 0

    BROWN FRANKLIN D

    • Director
    64,700 2011-11-03 0

    ELLIOTT ASSOCIATES, L.P.

    • 10% Owner
    No longer subject to file 2010-12-14 0

    ELLIOTT INTERNATIONAL, L.P.

    • 10% Owner
    No longer subject to file 2010-12-14 0

    ODONNELL JEFFREY F

    • Director
    0 2010-05-20 0

    MCCORMICK PAUL

    • Director
    333 2010-04-30 0

    HAWKINS DANIEL VICE PRES - GLOBAL MARKETING

    • Officer
    0 2009-04-10 0

    DIETHRICH EDWARD

    • Director
    0 2008-05-22 0

    UYESUGI KAREN VICE PRESIDENT

    • Officer
    166,900 2007-10-30 0

    COELYN RONALD H

    • Director
    20,000 2007-05-22 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    Elevate your investments